Personalized Medicine In Neurology Market
Personalized Medicine in Neurology Market Forecasts to 2032 – Global Analysis By Therapy Type (Pharmacogenomics, Digital Therapeutics, Biomarker-Based Diagnostics and Targeted Therapeutics), Technology, Application, End User and By Geography
According to Stratistics MRC, the Global Personalized Medicine in Neurology Market is accounted for $576.8 billion in 2025 and is expected to reach $1,021.1 billion by 2032 growing at a CAGR of 8.5% during the forecast period. Personalized medicine in neurology is a patient-centered approach that tailor’s diagnosis, treatment, and prevention strategies to an individual’s unique genetic, biomarker, environmental, and lifestyle profile. It moves beyond the “one-size-fits-all” model by integrating advanced technologies like genomics, neuroimaging, and data analytics to understand disease mechanisms at a personal level. This approach enhances precision in managing neurological disorders such as epilepsy, Alzheimer’s disease, and multiple sclerosis, improving outcomes and minimizing side effects. Personalized neurology also fosters early detection and targeted therapies, empowering clinicians to deliver care that is more effective, predictive, and responsive to each patient’s distinct neurological makeup.
Market Dynamics:
Driver:
Rising Prevalence of Neurological Disorders
The rising prevalence of neurological disorders is accelerating advancements in personalized medicine, transforming neurology into a more precise and patient-centric field. With increased demand, researchers are harnessing genetic, biomarker, and lifestyle data to tailor treatments for conditions like Alzheimer’s and Parkinson’s. This shift fosters innovation in diagnostics and therapeutics, empowering clinicians to deliver more effective, individualized care—ultimately improving outcomes and quality of life for millions affected by neurological diseases.
Restraint:
High Cost of Personalized Treatments
The high cost of personalized treatments in neurology significantly hinders accessibility and equity in care. Many patients, especially in low-resource settings, cannot afford advanced genomic testing or tailored therapies, leading to disparities in treatment outcomes. This financial barrier slows widespread adoption, limits clinical trials, and discourages investment in scalable solutions. Ultimately, it undermines the promise of personalized medicine to deliver precise, effective neurological care for all individuals.
Opportunity:
Advancements in Genomics and Molecular Diagnostics
Advancements in genomics and molecular diagnostics have revolutionized personalized medicine in neurology by enabling precise identification of genetic mutations and biomarkers. These innovations allow tailored treatments for conditions like epilepsy, Alzheimer’s, and Parkinson’s, improving efficacy and reducing side effects. Early diagnosis and risk prediction empower proactive care, while gene-targeted therapies offer hope for previously untreatable disorders. Together, they drive a transformative shift toward individualized, data-driven neurological healthcare.
Threat:
Complex Regulatory Landscape
The complex regulatory landscape significantly hampers the advancement of personalized medicine in neurology. Stringent approval processes, fragmented global standards, and slow adaptation to emerging technologies delay innovation and patient access. Regulatory ambiguity around genetic data and biomarkers further complicates clinical integration. These barriers discourage investment, stifle collaboration, and limit tailored treatment options, ultimately impeding progress in delivering precise, effective neurological care to patients who need it most.
Covid-19 Impact
The Covid-19 pandemic accelerated the adoption of personalized medicine in neurology by highlighting the need for precision care and remote diagnostics. It spurred innovation in telemedicine, digital health platforms, and genomic research, enabling tailored neurological treatments despite healthcare disruptions. However, resource diversion and delayed clinical trials temporarily hindered progress. Overall, the crisis underscored the value of individualized approaches in managing neurological conditions, fostering resilience and adaptability in care delivery.
The alzheimer's disease segment is expected to be the largest during the forecast period
The alzheimer's disease segment is expected to account for the largest market share during the forecast period, due to urgent need for more effective, individualized treatments. Personalized medicine enables early detection and tailored therapeutic strategies using genomics and biomarkers, which are especially critical in managing Alzheimer’s progression. With increasing research investments and technological advancements, this segment benefits from precision diagnostics and targeted interventions, significantly improving patient outcomes and reducing the burden on caregivers and healthcare systems.
The microarray segment is expected to have the highest CAGR during the forecast period
Over the forecast period, the microarray segment is predicted to witness the highest growth rate, due to its ability to analyze thousands of genetic markers simultaneously. This technology plays a pivotal role in identifying disease-specific biomarkers and tailoring treatments to individual neurological profiles. Its growing adoption in clinical settings for early diagnosis and personalized therapy selection enhances its market potential. As demand for precision medicine rises, microarrays offer scalable, cost-effective solutions that support the expansion of personalized neurology applications.
Region with largest share:
During the forecast period, the Asia Pacific region is expected to hold the largest market share due to its vast patient population, increasing healthcare investments, and growing awareness of neurological disorders. Countries like China, India, and Japan are rapidly adopting advanced diagnostic technologies and personalized treatment approaches. Government initiatives promoting genomics research and healthcare digitization further fuel market growth. The region’s expanding medical infrastructure and rising demand for tailored therapies make it a key driver in the global neurology personalization landscape.
Region with highest CAGR:
Over the forecast period, the North America region is anticipated to exhibit the highest CAGR, owing to robust research infrastructure, high healthcare spending, and early adoption of innovative technologies. The region benefits from strong collaborations between academic institutions, biotech firms, and healthcare providers, accelerating the development of genomic and molecular diagnostic tools. Favorable regulatory frameworks and increasing prevalence of neurological disorders like Alzheimer’s and multiple sclerosis further boost demand for personalized treatments, positioning North America as a growth leader.
Key players in the market
Some of the key players profiled in the Personalized Medicine in Neurology Market include Roche Holding AG, Thermo Fisher Scientific Inc., Novartis AG, Becton, Dickinson and Company (BD), Biogen Inc., Merck & Co., Inc., Johnson & Johnson, Siemens Healthineers, Pfizer Inc., Abbott Laboratories, GlaxoSmithKline plc (GSK), Eli Lilly and Company, Amgen Inc., Illumina, Inc., Neurocrine Biosciences, Inc., QIAGEN N.V., PerkinElmer, Inc. and Agilent Technologies, Inc.
Key Developments:
In August 2025, Novartis has entered a collaboration with BioArctic to harness their BrainTransporter platform, aiming to develop novel neurological therapeutics. BioArctic will combine its BrainTransporter technology with a Novartis proprietary antibody to generate drug candidates.
In July 2025, Novartis has entered a collaboration with BioArctic to harness their BrainTransporter platform, aiming to develop novel neurological therapeutics. BioArctic will combine its BrainTransporter technology with a Novartis proprietary antibody to generate drug candidates.
Therapy Types Covered:
• Pharmacogenomics
• Digital Therapeutics
• Biomarker-Based Diagnostics
• Targeted Therapeutics
Technologies Covered:
• Next-Generation Sequencing (NGS)
• CRISPR-based Diagnostics
• Polymerase Chain Reaction (PCR)
• Microarray
• Other Technologies
Applications Covered:
• Alzheimer's Disease
• Multiple Sclerosis
• Parkinson’s Disease
• Epilepsy
• Stroke
• Other Neurological Disorders
End Users Covered:
• Hospitals & Clinics
• Research Institutes
• Diagnostic Laboratories
• Pharmaceutical & Biotechnology Companies
Regions Covered:
• North America
o US
o Canada
o Mexico
• Europe
o Germany
o UK
o Italy
o France
o Spain
o Rest of Europe
• Asia Pacific
o Japan
o China
o India
o Australia
o New Zealand
o South Korea
o Rest of Asia Pacific
• South America
o Argentina
o Brazil
o Chile
o Rest of South America
• Middle East & Africa
o Saudi Arabia
o UAE
o Qatar
o South Africa
o Rest of Middle East & Africa
What our report offers:
- Market share assessments for the regional and country-level segments
- Strategic recommendations for the new entrants
- Covers Market data for the years 2024, 2025, 2026, 2028, and 2032
- Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
- Strategic recommendations in key business segments based on the market estimations
- Competitive landscaping mapping the key common trends
- Company profiling with detailed strategies, financials, and recent developments
- Supply chain trends mapping the latest technological advancements
Free Customization Offerings:
All the customers of this report will be entitled to receive one of the following free customization options:
• Company Profiling
o Comprehensive profiling of additional market players (up to 3)
o SWOT Analysis of key players (up to 3)
• Regional Segmentation
o Market estimations, Forecasts and CAGR of any prominent country as per the client's interest (Note: Depends on feasibility check)
• Competitive Benchmarking
o Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances
Table of Contents
1 Executive Summary
2 Preface
2.1 Abstract
2.2 Stake Holders
2.3 Research Scope
2.4 Research Methodology
2.4.1 Data Mining
2.4.2 Data Analysis
2.4.3 Data Validation
2.4.4 Research Approach
2.5 Research Sources
2.5.1 Primary Research Sources
2.5.2 Secondary Research Sources
2.5.3 Assumptions
3 Market Trend Analysis
3.1 Introduction
3.2 Drivers
3.3 Restraints
3.4 Opportunities
3.5 Threats
3.6 Technology Analysis
3.7 Application Analysis
3.8 End User Analysis
3.9 Emerging Markets
3.10 Impact of Covid-19
4 Porters Five Force Analysis
4.1 Bargaining power of suppliers
4.2 Bargaining power of buyers
4.3 Threat of substitutes
4.4 Threat of new entrants
4.5 Competitive rivalry
5 Global Personalized Medicine in Neurology Market, By Therapy Type
5.1 Introduction
5.2 Pharmacogenomics
5.3 Digital Therapeutics
5.4 Biomarker-Based Diagnostics
5.5 Targeted Therapeutics
6 Global Personalized Medicine in Neurology Market, By Technology
6.1 Introduction
6.2 Next-Generation Sequencing (NGS)
6.3 CRISPR-based Diagnostics
6.4 Polymerase Chain Reaction (PCR)
6.5 Microarray
6.6 Other Technologies
7 Global Personalized Medicine in Neurology Market, By Application
7.1 Introduction
7.2 Alzheimer's Disease
7.3 Multiple Sclerosis
7.4 Parkinson’s Disease
7.5 Epilepsy
7.6 Stroke
7.7 Other Neurological Disorders
8 Global Personalized Medicine in Neurology Market, By End User
8.1 Introduction
8.2 Hospitals & Clinics
8.3 Research Institutes
8.4 Diagnostic Laboratories
8.5 Pharmaceutical & Biotechnology Companies
9 Global Personalized Medicine in Neurology Market, By Geography
9.1 Introduction
9.2 North America
9.2.1 US
9.2.2 Canada
9.2.3 Mexico
9.3 Europe
9.3.1 Germany
9.3.2 UK
9.3.3 Italy
9.3.4 France
9.3.5 Spain
9.3.6 Rest of Europe
9.4 Asia Pacific
9.4.1 Japan
9.4.2 China
9.4.3 India
9.4.4 Australia
9.4.5 New Zealand
9.4.6 South Korea
9.4.7 Rest of Asia Pacific
9.5 South America
9.5.1 Argentina
9.5.2 Brazil
9.5.3 Chile
9.5.4 Rest of South America
9.6 Middle East & Africa
9.6.1 Saudi Arabia
9.6.2 UAE
9.6.3 Qatar
9.6.4 South Africa
9.6.5 Rest of Middle East & Africa
10 Key Developments
10.1 Agreements, Partnerships, Collaborations and Joint Ventures
10.2 Acquisitions & Mergers
10.3 New Product Launch
10.4 Expansions
10.5 Other Key Strategies
11 Company Profiling
11.1 Roche Holding AG
11.2 Thermo Fisher Scientific Inc.
11.3 Novartis AG
11.4 Becton, Dickinson and Company (BD)
11.5 Biogen Inc.
11.6 Merck & Co., Inc.
11.7 Johnson & Johnson
11.8 Siemens Healthineers
11.9 Pfizer Inc.
11.10 Abbott Laboratories
11.11 GlaxoSmithKline plc (GSK)
11.12 Eli Lilly and Company
11.13 Amgen Inc.
11.14 Illumina, Inc.
11.15 Neurocrine Biosciences, Inc.
11.16 QIAGEN N.V.
11.17 PerkinElmer, Inc.
11.18 Agilent Technologies, Inc.
List of Tables
1 Global Personalized Medicine in Neurology Market Outlook, By Region (2024-2032) ($MN)
2 Global Personalized Medicine in Neurology Market Outlook, By Therapy Type (2024-2032) ($MN)
3 Global Personalized Medicine in Neurology Market Outlook, By Pharmacogenomics (2024-2032) ($MN)
4 Global Personalized Medicine in Neurology Market Outlook, By Digital Therapeutics (2024-2032) ($MN)
5 Global Personalized Medicine in Neurology Market Outlook, By Biomarker-Based Diagnostics (2024-2032) ($MN)
6 Global Personalized Medicine in Neurology Market Outlook, By Targeted Therapeutics (2024-2032) ($MN)
7 Global Personalized Medicine in Neurology Market Outlook, By Technology (2024-2032) ($MN)
8 Global Personalized Medicine in Neurology Market Outlook, By Next-Generation Sequencing (NGS) (2024-2032) ($MN)
9 Global Personalized Medicine in Neurology Market Outlook, By CRISPR-based Diagnostics (2024-2032) ($MN)
10 Global Personalized Medicine in Neurology Market Outlook, By Polymerase Chain Reaction (PCR) (2024-2032) ($MN)
11 Global Personalized Medicine in Neurology Market Outlook, By Microarray (2024-2032) ($MN)
12 Global Personalized Medicine in Neurology Market Outlook, By Other Technologies (2024-2032) ($MN)
13 Global Personalized Medicine in Neurology Market Outlook, By Application (2024-2032) ($MN)
14 Global Personalized Medicine in Neurology Market Outlook, By Alzheimer's Disease (2024-2032) ($MN)
15 Global Personalized Medicine in Neurology Market Outlook, By Multiple Sclerosis (2024-2032) ($MN)
16 Global Personalized Medicine in Neurology Market Outlook, By Parkinson’s Disease (2024-2032) ($MN)
17 Global Personalized Medicine in Neurology Market Outlook, By Epilepsy (2024-2032) ($MN)
18 Global Personalized Medicine in Neurology Market Outlook, By Stroke (2024-2032) ($MN)
19 Global Personalized Medicine in Neurology Market Outlook, By Other Neurological Disorders (2024-2032) ($MN)
20 Global Personalized Medicine in Neurology Market Outlook, By End User (2024-2032) ($MN)
21 Global Personalized Medicine in Neurology Market Outlook, By Hospitals & Clinics (2024-2032) ($MN)
22 Global Personalized Medicine in Neurology Market Outlook, By Research Institutes (2024-2032) ($MN)
23 Global Personalized Medicine in Neurology Market Outlook, By Diagnostic Laboratories (2024-2032) ($MN)
24 Global Personalized Medicine in Neurology Market Outlook, By Pharmaceutical & Biotechnology Companies (2024-2032) ($MN)
25 North America Personalized Medicine in Neurology Market Outlook, By Country (2024-2032) ($MN)
26 North America Personalized Medicine in Neurology Market Outlook, By Therapy Type (2024-2032) ($MN)
27 North America Personalized Medicine in Neurology Market Outlook, By Pharmacogenomics (2024-2032) ($MN)
28 North America Personalized Medicine in Neurology Market Outlook, By Digital Therapeutics (2024-2032) ($MN)
29 North America Personalized Medicine in Neurology Market Outlook, By Biomarker-Based Diagnostics (2024-2032) ($MN)
30 North America Personalized Medicine in Neurology Market Outlook, By Targeted Therapeutics (2024-2032) ($MN)
31 North America Personalized Medicine in Neurology Market Outlook, By Technology (2024-2032) ($MN)
32 North America Personalized Medicine in Neurology Market Outlook, By Next-Generation Sequencing (NGS) (2024-2032) ($MN)
33 North America Personalized Medicine in Neurology Market Outlook, By CRISPR-based Diagnostics (2024-2032) ($MN)
34 North America Personalized Medicine in Neurology Market Outlook, By Polymerase Chain Reaction (PCR) (2024-2032) ($MN)
35 North America Personalized Medicine in Neurology Market Outlook, By Microarray (2024-2032) ($MN)
36 North America Personalized Medicine in Neurology Market Outlook, By Other Technologies (2024-2032) ($MN)
37 North America Personalized Medicine in Neurology Market Outlook, By Application (2024-2032) ($MN)
38 North America Personalized Medicine in Neurology Market Outlook, By Alzheimer's Disease (2024-2032) ($MN)
39 North America Personalized Medicine in Neurology Market Outlook, By Multiple Sclerosis (2024-2032) ($MN)
40 North America Personalized Medicine in Neurology Market Outlook, By Parkinson’s Disease (2024-2032) ($MN)
41 North America Personalized Medicine in Neurology Market Outlook, By Epilepsy (2024-2032) ($MN)
42 North America Personalized Medicine in Neurology Market Outlook, By Stroke (2024-2032) ($MN)
43 North America Personalized Medicine in Neurology Market Outlook, By Other Neurological Disorders (2024-2032) ($MN)
44 North America Personalized Medicine in Neurology Market Outlook, By End User (2024-2032) ($MN)
45 North America Personalized Medicine in Neurology Market Outlook, By Hospitals & Clinics (2024-2032) ($MN)
46 North America Personalized Medicine in Neurology Market Outlook, By Research Institutes (2024-2032) ($MN)
47 North America Personalized Medicine in Neurology Market Outlook, By Diagnostic Laboratories (2024-2032) ($MN)
48 North America Personalized Medicine in Neurology Market Outlook, By Pharmaceutical & Biotechnology Companies (2024-2032) ($MN)
49 Europe Personalized Medicine in Neurology Market Outlook, By Country (2024-2032) ($MN)
50 Europe Personalized Medicine in Neurology Market Outlook, By Therapy Type (2024-2032) ($MN)
51 Europe Personalized Medicine in Neurology Market Outlook, By Pharmacogenomics (2024-2032) ($MN)
52 Europe Personalized Medicine in Neurology Market Outlook, By Digital Therapeutics (2024-2032) ($MN)
53 Europe Personalized Medicine in Neurology Market Outlook, By Biomarker-Based Diagnostics (2024-2032) ($MN)
54 Europe Personalized Medicine in Neurology Market Outlook, By Targeted Therapeutics (2024-2032) ($MN)
55 Europe Personalized Medicine in Neurology Market Outlook, By Technology (2024-2032) ($MN)
56 Europe Personalized Medicine in Neurology Market Outlook, By Next-Generation Sequencing (NGS) (2024-2032) ($MN)
57 Europe Personalized Medicine in Neurology Market Outlook, By CRISPR-based Diagnostics (2024-2032) ($MN)
58 Europe Personalized Medicine in Neurology Market Outlook, By Polymerase Chain Reaction (PCR) (2024-2032) ($MN)
59 Europe Personalized Medicine in Neurology Market Outlook, By Microarray (2024-2032) ($MN)
60 Europe Personalized Medicine in Neurology Market Outlook, By Other Technologies (2024-2032) ($MN)
61 Europe Personalized Medicine in Neurology Market Outlook, By Application (2024-2032) ($MN)
62 Europe Personalized Medicine in Neurology Market Outlook, By Alzheimer's Disease (2024-2032) ($MN)
63 Europe Personalized Medicine in Neurology Market Outlook, By Multiple Sclerosis (2024-2032) ($MN)
64 Europe Personalized Medicine in Neurology Market Outlook, By Parkinson’s Disease (2024-2032) ($MN)
65 Europe Personalized Medicine in Neurology Market Outlook, By Epilepsy (2024-2032) ($MN)
66 Europe Personalized Medicine in Neurology Market Outlook, By Stroke (2024-2032) ($MN)
67 Europe Personalized Medicine in Neurology Market Outlook, By Other Neurological Disorders (2024-2032) ($MN)
68 Europe Personalized Medicine in Neurology Market Outlook, By End User (2024-2032) ($MN)
69 Europe Personalized Medicine in Neurology Market Outlook, By Hospitals & Clinics (2024-2032) ($MN)
70 Europe Personalized Medicine in Neurology Market Outlook, By Research Institutes (2024-2032) ($MN)
71 Europe Personalized Medicine in Neurology Market Outlook, By Diagnostic Laboratories (2024-2032) ($MN)
72 Europe Personalized Medicine in Neurology Market Outlook, By Pharmaceutical & Biotechnology Companies (2024-2032) ($MN)
73 Asia Pacific Personalized Medicine in Neurology Market Outlook, By Country (2024-2032) ($MN)
74 Asia Pacific Personalized Medicine in Neurology Market Outlook, By Therapy Type (2024-2032) ($MN)
75 Asia Pacific Personalized Medicine in Neurology Market Outlook, By Pharmacogenomics (2024-2032) ($MN)
76 Asia Pacific Personalized Medicine in Neurology Market Outlook, By Digital Therapeutics (2024-2032) ($MN)
77 Asia Pacific Personalized Medicine in Neurology Market Outlook, By Biomarker-Based Diagnostics (2024-2032) ($MN)
78 Asia Pacific Personalized Medicine in Neurology Market Outlook, By Targeted Therapeutics (2024-2032) ($MN)
79 Asia Pacific Personalized Medicine in Neurology Market Outlook, By Technology (2024-2032) ($MN)
80 Asia Pacific Personalized Medicine in Neurology Market Outlook, By Next-Generation Sequencing (NGS) (2024-2032) ($MN)
81 Asia Pacific Personalized Medicine in Neurology Market Outlook, By CRISPR-based Diagnostics (2024-2032) ($MN)
82 Asia Pacific Personalized Medicine in Neurology Market Outlook, By Polymerase Chain Reaction (PCR) (2024-2032) ($MN)
83 Asia Pacific Personalized Medicine in Neurology Market Outlook, By Microarray (2024-2032) ($MN)
84 Asia Pacific Personalized Medicine in Neurology Market Outlook, By Other Technologies (2024-2032) ($MN)
85 Asia Pacific Personalized Medicine in Neurology Market Outlook, By Application (2024-2032) ($MN)
86 Asia Pacific Personalized Medicine in Neurology Market Outlook, By Alzheimer's Disease (2024-2032) ($MN)
87 Asia Pacific Personalized Medicine in Neurology Market Outlook, By Multiple Sclerosis (2024-2032) ($MN)
88 Asia Pacific Personalized Medicine in Neurology Market Outlook, By Parkinson’s Disease (2024-2032) ($MN)
89 Asia Pacific Personalized Medicine in Neurology Market Outlook, By Epilepsy (2024-2032) ($MN)
90 Asia Pacific Personalized Medicine in Neurology Market Outlook, By Stroke (2024-2032) ($MN)
91 Asia Pacific Personalized Medicine in Neurology Market Outlook, By Other Neurological Disorders (2024-2032) ($MN)
92 Asia Pacific Personalized Medicine in Neurology Market Outlook, By End User (2024-2032) ($MN)
93 Asia Pacific Personalized Medicine in Neurology Market Outlook, By Hospitals & Clinics (2024-2032) ($MN)
94 Asia Pacific Personalized Medicine in Neurology Market Outlook, By Research Institutes (2024-2032) ($MN)
95 Asia Pacific Personalized Medicine in Neurology Market Outlook, By Diagnostic Laboratories (2024-2032) ($MN)
96 Asia Pacific Personalized Medicine in Neurology Market Outlook, By Pharmaceutical & Biotechnology Companies (2024-2032) ($MN)
97 South America Personalized Medicine in Neurology Market Outlook, By Country (2024-2032) ($MN)
98 South America Personalized Medicine in Neurology Market Outlook, By Therapy Type (2024-2032) ($MN)
99 South America Personalized Medicine in Neurology Market Outlook, By Pharmacogenomics (2024-2032) ($MN)
100 South America Personalized Medicine in Neurology Market Outlook, By Digital Therapeutics (2024-2032) ($MN)
101 South America Personalized Medicine in Neurology Market Outlook, By Biomarker-Based Diagnostics (2024-2032) ($MN)
102 South America Personalized Medicine in Neurology Market Outlook, By Targeted Therapeutics (2024-2032) ($MN)
103 South America Personalized Medicine in Neurology Market Outlook, By Technology (2024-2032) ($MN)
104 South America Personalized Medicine in Neurology Market Outlook, By Next-Generation Sequencing (NGS) (2024-2032) ($MN)
105 South America Personalized Medicine in Neurology Market Outlook, By CRISPR-based Diagnostics (2024-2032) ($MN)
106 South America Personalized Medicine in Neurology Market Outlook, By Polymerase Chain Reaction (PCR) (2024-2032) ($MN)
107 South America Personalized Medicine in Neurology Market Outlook, By Microarray (2024-2032) ($MN)
108 South America Personalized Medicine in Neurology Market Outlook, By Other Technologies (2024-2032) ($MN)
109 South America Personalized Medicine in Neurology Market Outlook, By Application (2024-2032) ($MN)
110 South America Personalized Medicine in Neurology Market Outlook, By Alzheimer's Disease (2024-2032) ($MN)
111 South America Personalized Medicine in Neurology Market Outlook, By Multiple Sclerosis (2024-2032) ($MN)
112 South America Personalized Medicine in Neurology Market Outlook, By Parkinson’s Disease (2024-2032) ($MN)
113 South America Personalized Medicine in Neurology Market Outlook, By Epilepsy (2024-2032) ($MN)
114 South America Personalized Medicine in Neurology Market Outlook, By Stroke (2024-2032) ($MN)
115 South America Personalized Medicine in Neurology Market Outlook, By Other Neurological Disorders (2024-2032) ($MN)
116 South America Personalized Medicine in Neurology Market Outlook, By End User (2024-2032) ($MN)
117 South America Personalized Medicine in Neurology Market Outlook, By Hospitals & Clinics (2024-2032) ($MN)
118 South America Personalized Medicine in Neurology Market Outlook, By Research Institutes (2024-2032) ($MN)
119 South America Personalized Medicine in Neurology Market Outlook, By Diagnostic Laboratories (2024-2032) ($MN)
120 South America Personalized Medicine in Neurology Market Outlook, By Pharmaceutical & Biotechnology Companies (2024-2032) ($MN)
121 Middle East & Africa Personalized Medicine in Neurology Market Outlook, By Country (2024-2032) ($MN)
122 Middle East & Africa Personalized Medicine in Neurology Market Outlook, By Therapy Type (2024-2032) ($MN)
123 Middle East & Africa Personalized Medicine in Neurology Market Outlook, By Pharmacogenomics (2024-2032) ($MN)
124 Middle East & Africa Personalized Medicine in Neurology Market Outlook, By Digital Therapeutics (2024-2032) ($MN)
125 Middle East & Africa Personalized Medicine in Neurology Market Outlook, By Biomarker-Based Diagnostics (2024-2032) ($MN)
126 Middle East & Africa Personalized Medicine in Neurology Market Outlook, By Targeted Therapeutics (2024-2032) ($MN)
127 Middle East & Africa Personalized Medicine in Neurology Market Outlook, By Technology (2024-2032) ($MN)
128 Middle East & Africa Personalized Medicine in Neurology Market Outlook, By Next-Generation Sequencing (NGS) (2024-2032) ($MN)
129 Middle East & Africa Personalized Medicine in Neurology Market Outlook, By CRISPR-based Diagnostics (2024-2032) ($MN)
130 Middle East & Africa Personalized Medicine in Neurology Market Outlook, By Polymerase Chain Reaction (PCR) (2024-2032) ($MN)
131 Middle East & Africa Personalized Medicine in Neurology Market Outlook, By Microarray (2024-2032) ($MN)
132 Middle East & Africa Personalized Medicine in Neurology Market Outlook, By Other Technologies (2024-2032) ($MN)
133 Middle East & Africa Personalized Medicine in Neurology Market Outlook, By Application (2024-2032) ($MN)
134 Middle East & Africa Personalized Medicine in Neurology Market Outlook, By Alzheimer's Disease (2024-2032) ($MN)
135 Middle East & Africa Personalized Medicine in Neurology Market Outlook, By Multiple Sclerosis (2024-2032) ($MN)
136 Middle East & Africa Personalized Medicine in Neurology Market Outlook, By Parkinson’s Disease (2024-2032) ($MN)
137 Middle East & Africa Personalized Medicine in Neurology Market Outlook, By Epilepsy (2024-2032) ($MN)
138 Middle East & Africa Personalized Medicine in Neurology Market Outlook, By Stroke (2024-2032) ($MN)
139 Middle East & Africa Personalized Medicine in Neurology Market Outlook, By Other Neurological Disorders (2024-2032) ($MN)
140 Middle East & Africa Personalized Medicine in Neurology Market Outlook, By End User (2024-2032) ($MN)
141 Middle East & Africa Personalized Medicine in Neurology Market Outlook, By Hospitals & Clinics (2024-2032) ($MN)
142 Middle East & Africa Personalized Medicine in Neurology Market Outlook, By Research Institutes (2024-2032) ($MN)
143 Middle East & Africa Personalized Medicine in Neurology Market Outlook, By Diagnostic Laboratories (2024-2032) ($MN)
144 Middle East & Africa Personalized Medicine in Neurology Market Outlook, By Pharmaceutical & Biotechnology Companies (2024-2032) ($MN)
List of Figures
RESEARCH METHODOLOGY
We at ‘Stratistics’ opt for an extensive research approach which involves data mining, data validation, and data analysis. The various research sources include in-house repository, secondary research, competitor’s sources, social media research, client internal data, and primary research.
Our team of analysts prefers the most reliable and authenticated data sources in order to perform the comprehensive literature search. With access to most of the authenticated data bases our team highly considers the best mix of information through various sources to obtain extensive and accurate analysis.
Each report takes an average time of a month and a team of 4 industry analysts. The time may vary depending on the scope and data availability of the desired market report. The various parameters used in the market assessment are standardized in order to enhance the data accuracy.
Data Mining
The data is collected from several authenticated, reliable, paid and unpaid sources and is filtered depending on the scope & objective of the research. Our reports repository acts as an added advantage in this procedure. Data gathering from the raw material suppliers, distributors and the manufacturers is performed on a regular basis, this helps in the comprehensive understanding of the products value chain. Apart from the above mentioned sources the data is also collected from the industry consultants to ensure the objective of the study is in the right direction.
Market trends such as technological advancements, regulatory affairs, market dynamics (Drivers, Restraints, Opportunities and Challenges) are obtained from scientific journals, market related national & international associations and organizations.
Data Analysis
From the data that is collected depending on the scope & objective of the research the data is subjected for the analysis. The critical steps that we follow for the data analysis include:
- Product Lifecycle Analysis
- Competitor analysis
- Risk analysis
- Porters Analysis
- PESTEL Analysis
- SWOT Analysis
The data engineering is performed by the core industry experts considering both the Marketing Mix Modeling and the Demand Forecasting. The marketing mix modeling makes use of multiple-regression techniques to predict the optimal mix of marketing variables. Regression factor is based on a number of variables and how they relate to an outcome such as sales or profits.
Data Validation
The data validation is performed by the exhaustive primary research from the expert interviews. This includes telephonic interviews, focus groups, face to face interviews, and questionnaires to validate our research from all aspects. The industry experts we approach come from the leading firms, involved in the supply chain ranging from the suppliers, distributors to the manufacturers and consumers so as to ensure an unbiased analysis.
We are in touch with more than 15,000 industry experts with the right mix of consultants, CEO's, presidents, vice presidents, managers, experts from both supply side and demand side, executives and so on.
The data validation involves the primary research from the industry experts belonging to:
- Leading Companies
- Suppliers & Distributors
- Manufacturers
- Consumers
- Industry/Strategic Consultants
Apart from the data validation the primary research also helps in performing the fill gap research, i.e. providing solutions for the unmet needs of the research which helps in enhancing the reports quality.
For more details about research methodology, kindly write to us at info@strategymrc.com
Frequently Asked Questions
In case of any queries regarding this report, you can contact the customer service by filing the “Inquiry Before Buy” form available on the right hand side. You may also contact us through email: info@strategymrc.com or phone: +1-301-202-5929
Yes, the samples are available for all the published reports. You can request them by filling the “Request Sample” option available in this page.
Yes, you can request a sample with your specific requirements. All the customized samples will be provided as per the requirement with the real data masked.
All our reports are available in Digital PDF format. In case if you require them in any other formats, such as PPT, Excel etc you can submit a request through “Inquiry Before Buy” form available on the right hand side. You may also contact us through email: info@strategymrc.com or phone: +1-301-202-5929
We offer a free 15% customization with every purchase. This requirement can be fulfilled for both pre and post sale. You may send your customization requirements through email at info@strategymrc.com or call us on +1-301-202-5929.
We have 3 different licensing options available in electronic format.
- Single User Licence: Allows one person, typically the buyer, to have access to the ordered product. The ordered product cannot be distributed to anyone else.
- 2-5 User Licence: Allows the ordered product to be shared among a maximum of 5 people within your organisation.
- Corporate License: Allows the product to be shared among all employees of your organisation regardless of their geographical location.
All our reports are typically be emailed to you as an attachment.
To order any available report you need to register on our website. The payment can be made either through CCAvenue or PayPal payments gateways which accept all international cards.
We extend our support to 6 months post sale. A post sale customization is also provided to cover your unmet needs in the report.
Request Customization
We offer complimentary customization of up to 15% with every purchase. To share your customization requirements, feel free to email us at info@strategymrc.com or call us on +1-301-202-5929. .
Please Note: Customization within the 15% threshold is entirely free of charge. If your request exceeds this limit, we will conduct a feasibility assessment. Following that, a detailed quote and timeline will be provided.
WHY CHOOSE US ?
Assured Quality
Best in class reports with high standard of research integrity
24X7 Research Support
Continuous support to ensure the best customer experience.
Free Customization
Adding more values to your product of interest.
Safe & Secure Access
Providing a secured environment for all online transactions.
Trusted by 600+ Brands
Serving the most reputed brands across the world.
